Evidence map›Paper›PMID 41951578›Full record

ArticleCell death & disease2026

Exosomal miR-92a-3p promotes pancreatic cancer cells' extravasation by inducing vascular permeability through inhibition of DAB2IP.

Luhan Li, Yanyan Cui, Miao Zhang, Tianyu Shen, Dekun Wang, Xue Mi, Yuying Zhang, Xiaoyue Tan, Alejandro Vaquero, Thomas Braun and 4 more

Abstract read
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Luhan Li *Department of Thoracic Surgery, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Nankai University, Tianjin, China.
Yanyan Cui *The Affiliated Hospital of Chifeng University, Chifeng, China.
Miao ZhangDepartment of Oncology, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Nankai University, Tianjin, China.
Tianyu ShenSchool of Medicine, State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China.
Dekun WangSchool of Medicine, State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China.
Xue MiSchool of Medicine, State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China.
Yuying ZhangSchool of Medicine, State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China.
Xiaoyue TanSchool of Medicine, State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China.ORCID http://orcid.org/0000-0003-3394-9063
Alejandro VaqueroChromatin Biology Laboratory, Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain.ORCID http://orcid.org/0000-0002-8735-4156
Thomas BraunDepartment of Cardiac Development and Remodeling, Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany.ORCID http://orcid.org/0000-0002-6165-4804
Jihui HaoNational Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.ORCID http://orcid.org/0000-0002-1607-1730
Alessandro IanniChromatin Biology Laboratory, Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain.ORCID http://orcid.org/0000-0001-7398-589X
Chunyang JiangDepartment of Thoracic Surgery, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Nankai University, Tianjin, China. chunyangjiang@126.com.ORCID http://orcid.org/0000-0002-7878-2829
Shijing YueDepartment of Thoracic Surgery, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Nankai University, Tianjin, China. shijingyue@nankai.edu.cn.ORCID http://orcid.org/0000-0002-9155-488X

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82573570Natural Science Foundation of Tianjin Municipal Science and Technology Commission (Natural Science Foundation of Tianjin Municipal Science & Technology Commission) 25JCYBJC01790
6 · The paper itself

Abstract

Metastasis, the colonization of distant organs by cells derived from primary cancer, is the leading cause of mortality in pancreatic adenocarcinoma (PAAD). Growing evidence indicates that cancer-derived exosomes play pivotal roles in facilitating cancer metastasis by promoting pre-metastatic niche formation. However, the contribution of PAAD-derived exosomal microRNAs (MiRNAs) to this process remains poorly characterized. In this study, we identified specific PAAD-derived exosomal miRNAs involved in metastatic progression. Sequencing of small RNAs extracted from circulating exosomes derived from patients with metastatic or non-metastatic PAAD revealed that miR-92a-3p is associated with a metastatic phenotype. We demonstrated that exosomal miR-92a-3p facilitates cancer cells' extravasation and lung metastasis by disrupting vascular barrier integrity. Mechanistically, exosomal miR-92a-3p directly inhibits the tumor suppressor disabled homolog 2 interacting protein (DAB2IP), thereby activating the PI3K-AKT signaling cascade in endothelial cells (ECs). This activation attenuates expression of intracellular junction markers and stimulates endothelial nitric oxide synthase, leading to increased vascular permeability. Our findings suggest that targeting miR-92a-3p could represent a potential strategy to reduce metastasis in PAAD.

Indexed as

Capillary PermeabilityExosomesMicroRNAsPancreatic Neoplasmsras GTPase-Activating ProteinsAdenocarcinomaAnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansMicePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal TransductionDAB2IP protein, humanMicroRNAsMIRN92 microRNA, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktras GTPase-Activating Proteins

Identifiers

PMID41951578
PMCPMC13187007

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.